Background: The damage of synapses and neurons leads to the cognitive impairment
and this is the root cause of progression of Alzheimer’s disease. The nematode
Caenorhabditis elegans is widely used as an in vivo model to study the synaptic transmission
because of the relatively modest worm nervous system, which is like mammals.
Objective: The aim of this work is to assess the effectiveness of resveratrol-loaded nanostructured
lipid carrier for the management of Alzheimer's disease.
Method: Resveratrol loaded nanostructured lipid carrier (RES-NLC) was prepared by
modified solvent emulsification-diffusion technique, using compritol 888ATO (solid
lipid), sesame oil (liquid lipid) and tween 80 (surfactant).
Results: Formulations were characterized via particle size (155.08±3.28 nm), polydispersity
index (PDI) (0.121), and zeta potential (-16.58). The entrapment efficiency was found
to be 79.65±2.52% and cumulative percentage drug release was 63.54% up to 8 hours.
Anticholinesterase inhibition competence was performed through Aldicarb assay. It was
found that surge in the dose of RES-NLC caused an increased worm paralysis, which was
credited to the accumulation of acetylcholine in synapses. Quantitative RT-PCR performed
showed the effect of formulation on acetylcholinesterase (AChE) AChE 1 and
AChE 2 genes. RES-NLC (dose 400 μg/ml) decreased the AChE 1 expression 3.23±0.13
fold whereas AChE 2 expression decreased 3.34±0.14 fold with the same dose. RES-NLC
displayed transfer latency and escape latency of 27.50 ± 2.34 and 30.17 ± 2.82.
Conclusion: Based on the results, it was concluded that RES-NLC was effective in increasing
acetylcholine concentration in synapses and thus in the treatment of Alzheimer's